The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GYRE | -33.12% | +3.98% | +0.78% | +16% |
| S&P | +19.17% | +69.21% | +11.09% | +59% |
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The company was founded on March 7, 1997 and is headquartered in San Diego, CA.
No news articles found for Gyre Therapeutics.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $37.20M | 33.4% |
| Gross Profit | $35.45M | 32.8% |
| Gross Margin | 95.31% | -0.5% |
| Market Cap | $641.69M | -38.2% |
| Market Cap / Employee | $128.34M | 0.0% |
| Employees | 5 | 0.0% |
| Net Income | -$1,366.00K | -340.1% |
| EBITDA | $7.58M | 61.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $37.07M | 213.8% |
| Accounts Receivable | $36.72M | 53.2% |
| Inventory | 10.2 | 60.5% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $303.00K | -65.8% |
| Short Term Debt | $636.00K | -10.8% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 3.45% | -6.5% |
| Return On Invested Capital | -90.15% | 19.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $4.32M | 339.8% |
| Operating Free Cash Flow | $4.99M | 197.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 103.42 | 161.17 | 450.92 | 195.80 | - |
| Price to Book | 10.52 | 9.46 | 7.36 | 6.30 | -61.67% |
| Price to Sales | 9.83 | 7.82 | 7.39 | 7.23 | 28.82% |
| Price to Tangible Book Value | 10.57 | 10.22 | 7.78 | 6.61 | -59.88% |
| Price to Free Cash Flow TTM | 37.82 | 27.82 | 744.36 | - | |
| Enterprise Value to EBITDA | 925.96 | 283.15 | 262.82 | 99.31 | -57.14% |
| Free Cash Flow Yield | 2.6% | 3.6% | 0.1% | - | |
| Return on Equity | 11.6% | 5.5% | 8.1% | 5.9% | -72.49% |
| Total Debt | $1.59M | $1.39M | $1.17M | $939.00K | -41.24% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
